Indeed, TP53-mutant CK-MDS patients had an OS of less than half that of non-mutant CK-MDS, relapsed quickly after different kinds of treatment, and hematopoietic clones with TP53 mutations were enriched after chemotherapy [82,96,98]. The gene discussed is TP53; the disease is myelodysplastic syndrome.